Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | GSK3B | P49841 | 5/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19380261 | 0.92 | KDM4E (0.54) | KDM4EGAAGSK3BMAPT | |
| SCHEMBL26887398 | 0.83 | SPHK1 (0.52) | — | |
| SCHEMBL30129915 | 0.83 | MAPT (0.61) | KDM4EGAAHDAC4HDAC6MAPT | |
| Hydrochloric Acid SCHEMBL26690918 | 0.82 | SPHK1 (0.51) | — | |
| SCHEMBL26887591 | 0.82 | KDM4E (0.49) | KDM4EGAAGSK3BHDAC4HDAC6 | |
| SCHEMBL19380008 | 0.80 | KDM4E (0.52) | KDM4EGAAMAPT | |
| SCHEMBL19380053 | 0.80 | MAOB (0.56) | KDM4EGAA | |
| SCHEMBL26887590 | 0.79 | KDM4E (0.51) | KDM4EGAAGSK3BHDAC4HDAC6 | |
| SCHEMBL19380242 | 0.78 | GSK3B (0.58) | KDM4EGSK3BMAPT | |
| SCHEMBL8544861 | 0.78 | SMPD1 (0.53) | KDM4EGAAGSK3BHDAC4HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373937-A1 | INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230373937-A1 | INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. | 2023-11-23 | — | — | US | disclosed |
| WO-2022056042-A1 | INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2022-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373937-A1 | INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY | SPNS2, SPCS2, SMN1; SMN2 | KDM4E 4256/4885GAA 3549/4885GSK3B 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.